HSCS experienced a severe financial deterioration with stockholders' equity collapsing from $7.3M to $205K and cash reserves declining dramatically from $5.8M to $1.1M.
The company's financial position has deteriorated substantially, with stockholders' equity nearly wiped out and cash reserves severely depleted, raising serious concerns about the company's ability to continue operations and fund its R&D activities. The significant increase in share count from 856K to 1.9M shares suggests substantial dilution occurred, likely through equity raises at unfavorable terms to maintain liquidity.
HSCS shows severe financial stress across all key metrics, with total assets declining from $9.5M to $4.2M and total liabilities increasing to $4.0M from $2.2M. Revenue declined substantially while R&D expenses increased meaningfully to $4.4M, indicating the company is burning through cash rapidly while generating minimal income. The dramatic reduction in stockholders' equity combined with the cash depletion suggests the company faced a liquidity crisis that required significant shareholder dilution to address.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Capex reduced 95.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Receivables surged 87.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Liabilities grew 83.8% — significant increase in debt or obligations, assess impact on financial flexibility.
Cash declined 81.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Revenue declined 76.6% — significant demand weakness or market share loss warrants investigation.
Current assets declined 70.5% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 55.6% — asset sales, write-downs, or balance sheet optimization underway.
R&D investment increased 52.4% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →